Skip to main content

Paying for Treatment

What's new

Lilly’s new basal insulin, Rezvoglar, may provide a cheaper alternative to Lantus. This marks the second approval of a biosimilar long-acting insulin. Continue Reading »

As we approach the new year, we want to remind you that if you've met your annual health insurance deductible or are close to meeting it, do not forget to order any diabetes supplies you need before your deductible resets on January 1 (in the US). Continue Reading »

For National Diabetes Awareness and Prevention Month, we asked members of the diaTribe community what access to care means to them. You can check out all of their responses here. Continue Reading »

A compromise reached among Congress and the Biden-Harris Administration would add a drug pricing plan to the Build Back Better Act that includes an insulin copay cap, a cap on annual out-of-pocket prescription drug costs, a rule allowing Medicare to negotiate prescription drug costs, and a drug inflation tax penalty. If passed, the proposed plan could improve access to diabetes care for millions. Continue Reading »

Ascensia Diabetes Care just launched a new Patient Assistance Program, which is now available in the US. The program aims to reduce out-of-pocket expenses for those who are starting or already using Senseonics’ Eversense 90-day implantable continuous glucose monitoring system. Continue Reading »

Medicare has updated its policy to now accept the inhaled insulin Afrezza, as well as injected insulin options to count towards the multiple daily administrations of insulin requirement for glucose monitoring systems coverage. Continue Reading »

Have you or someone you know had trouble affording diabetes care during COVID-19? During the pandemic, healthcare companies have created programs to help people get diabetes medications and devices. More than a year into COVID, which access programs exist, and how long we can expect them to stay in place? Continue Reading »